Affiliations 

  • 1 Knomics LLC, Skolkovo Innovation Center, Bolshoy Bulvar str., building 42, premise 1, room 1639, Moscow, 143026, Russia; Atlas Biomed Group, 31 Malaya Nikitskaya str., 121069, Moscow, Russia. Electronic address: kurina@atlas.ru
  • 2 Knomics LLC, Skolkovo Innovation Center, Bolshoy Bulvar str., building 42, premise 1, room 1639, Moscow, 143026, Russia; Atlas Biomed Group, 31 Malaya Nikitskaya str., 121069, Moscow, Russia
  • 3 Knomics LLC, Skolkovo Innovation Center, Bolshoy Bulvar str., building 42, premise 1, room 1639, Moscow, 143026, Russia; Center for Precision Genome Editing and Genetic Technologies for Biomedicine, Institute of Gene Biology Russian Academy of Sciences, 34/5 Vavilova str., 119334, Moscow, Russia
  • 4 Knomics LLC, Skolkovo Innovation Center, Bolshoy Bulvar str., building 42, premise 1, room 1639, Moscow, 143026, Russia
  • 5 Institute of Chemical Biology and Fundamental Medicine, Siberian Branch of the Russian Academy of Sciences, 8 Lavrentiev ave., Novosibirsk, 630090, Russia
  • 6 Knomics LLC, Skolkovo Innovation Center, Bolshoy Bulvar str., building 42, premise 1, room 1639, Moscow, 143026, Russia; Center for Precision Genome Editing and Genetic Technologies for Biomedicine, Institute of Gene Biology Russian Academy of Sciences, 34/5 Vavilova str., 119334, Moscow, Russia. Electronic address: a.tyakht@gmail.com
Mol Cell Probes, 2020 Aug;52:101570.
PMID: 32304824 DOI: 10.1016/j.mcp.2020.101570

Abstract

Nowadays the advent of innovative high-throughput sequencing allows obtaining high-quality microbiome profiling. However, PCR-based tests are still considered the "golden standard" for many clinical applications. Here, we designed a qPCR-based platform with fluorescent-labeled oligonucleotide probes for assessing human gut microbiome composition. The system allows conducting qualitative and semiquantitative analysis for 12 prokaryotic taxa that are prevalent in the human gut and associated with diseases, diet, age and other factors. The platform was validated by comparing microbiome profile data obtained with two different methods - the platform and high-throughput 16S rRNA sequencing - across 42 stool samples. The test can form the basis for precise and cost-efficient microbiome assay for large-scale surveys including clinical trials with interventions related to diet and disease risks.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.